Results 251 to 260 of about 452,625 (299)

Bacterial Infections of Skin and Skin Structures

2020
A 12-year-old female was evaluated in the emergency department (ED) for a swelling on her right leg. She is previously healthy; however, she has several mosquito bites on her leg which she has been scratching. Over the past 12 hours, she has had worsening redness and swelling around one of the mosquito bites, with associated fevers and vomiting. In the
Joseph Domachowske, Manika Suryadevara
openaire   +1 more source

Optimum Outpatient Therapy of Skin and Skin Structure Infections

Drugs, 1994
Skin and skin structure infections appear in a variety of ways with multiple aetiologies. Optimum therapy is accomplished with a good understanding of both skin anatomy and common resident or transient bacterial flora present on the skin surface. Primary and secondary infections occur in both immunocompetent and immunocompromised patients, each of ...
D M, Failla, G A, Pankey
openaire   +2 more sources

Fluoroquinolone Treatment of Skin and Skin Structure Infections

Drugs, 1999
When the causative pathogens are susceptible, the fluoroquinolones have been demonstrated to be highly efficacious in the treatment of both mild uncomplicated skin and skin structure infections as well as the more severe complicated infections involving these tissues, including infections of the feet of diabetic patients.
openaire   +2 more sources

Treatment of bacterial skin and skin structure infections

Expert Opinion on Pharmacotherapy, 2003
Bacterial skin and skin structure infections (SSSIs) are among the most frequently seen infectious entities in the community setting and occasionally in the institutional setting. A wide variety of SSSIs exist, with cellulitis, impetigo and folliculitis being the most common. Most SSSIs are caused by aerobic staphylococci and streptococci, with aerobic
openaire   +2 more sources

Emerging drugs for complicated skin and skin-structure infections

Expert Opinion on Emerging Drugs, 2010
IMPORTANCE OF THE FILED: With the worldwide surge of MRSA, skin and skin-structure infection (SSTI) treatment has become a challenge for physicians. Cultures and antibiotic susceptibility tests for SSTIs are the rule due to the implication in morbidity and mortality rates associated with MRSA infections.
Natalia, Mendoza, Stephen K, Tyring
openaire   +2 more sources

Skin and Skin Structure Infections in Older Adults

Current Geriatrics Reports, 2014
The aging population undergoes anatomical, physiological, and environmental changes, which puts them at increased risk for skin and skin structure infections. Skin and skin structure infections in older adults can range from simple cellulitis to life-threatening necrotizing fasciitis.
Jisha John, Kyle Miletic, Keith S. Kaye
openaire   +1 more source

Managing acute bacterial skin and skin structure infections

The Nurse Practitioner, 2017
Abstract: Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.
Allison M, Bell, S Travis, King, Katie E, Barber, Kim G, Adcock, Jamie L, Wagner, Kayla R, Stover   +5 more
openaire   +2 more sources

Dirithromycin in the treatment of skin and skin structure infections

Journal of Antimicrobial Chemotherapy, 1993
The efficacy and safety of dirithromycin were compared with those of erythromycin or miocamycin for the treatment of skin and/or skin structure infections in two double-blind, double-dummy, randomized, parallel group, multicentre studies conducted in North America and in Europe, and one single-blind, randomized, parallel group study conducted in Italy.
M, Derriennic, J P, Escande
openaire   +2 more sources

Loracarbef vs. cefaclor in pediatric skin and skin structure infections

The Pediatric Infectious Disease Journal, 1992
A double blind, randomized clinical trial involving 214 children, ages 6 months to 12 years, compared the safety and effectiveness of the new carbacephem loracarbef and the cephalosporin cefaclor for the treatment of skin and skin structure infections. The two agents were given primarily as oral suspensions.
M J, Hanfling, S A, Hausinger, J, Squires   +2 more
openaire   +2 more sources

Ceftobiprole medocaril for skin and skin-structure infections

Expert Opinion on Drug Metabolism & Toxicology
On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) as well as patients with Staphylococcus aureus bloodstream infections and patients 3 months to less than 18 years old with ...
openaire   +2 more sources